Preliminary results indicate that anti-BCMA CAR-T cell therapy, ciltacabtagene autleucel (cilta-cel), resulted in early, deep and durable responses in heavily pre-treated patients with MM. ORR was , sCR . Durability […]
This is an updated analysis of Zuma 5 – the CAR-T study of Axi-cel in follicular lymphoma (FL) and marginal zone lymphoma (MZL), initially reported in the mid-year conference season. […]
ZUMA-12 is the first study evaluating CAR T therapy first-line in high-risk LBCL. The results demonstrated an ORR of 85% and a CR in 74% of patients treated with Axi-Cel. […]
This is the first phase 1 study to explore dual antigen-targeting CAR-T cells in DLBCL. The very preliminary phase 1 data suggests several agents will be pushing to larger trials. […]
Further data from the TRANSCEND NHL 001 study supporting the role of CART therapy in mantle cell lymphoma. However it appears the rate of toxicity is just a little higher […]
This study evaluated the impact of prior lines of therapy on the efficacy of CAR-T and ASCT and found that OS was significantly longer, with a trend toward longer PFS, […]
Cytokine release syndrome is a well known complication of CAR-T therapy that can be treated with tocilizumab. This poster presents outcomes for patients treated with locally manufactured antiCD19 CAR-T cells […]
This poster presents follow-up data from the pivotal trial of brexucabtagene autoleucel (Tecartus) for mantle cell lymphoma showing that 75.1% of patients who achieve a CR following this CART, retain […]
This poster describes a clinical trial of tisagenlecleucel + ibrutinib that is currently recruiting in Australia. The trial allows very early recruitment of patients with MCL+genomic risk factors, or recruitment […]
